UroGen Pharma Ltd.
urogen.comUroGen Pharma Ltd (NASDAQ: URGN) is a specialty pharmaceutical company that develops and commercializes drug therapies for uro-oncology indications. Revenue comes from sales of two FDA-approved products: Jelmyto, a chemoablation agent for low-grade upper tract urothelial cancer (UTUC), and Zusduri, a chemoablative therapy for recurrent low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). Both products are built on the company's proprietary RTGel formulation technology, which increases dwell time and tissue coverage of mitomycin in the urinary tract. UroGen is incorporated in Israel and operates commercially in the United States, selling into hospitals, surgery centers, and clinics through a specialty sales force. The company focuses on reformulating previously approved drugs into RTGel-based intravesical delivery formats, positioning its products as alternatives to surgical resection for eligible patients.
Products & Services
Jelmyto: RTGel-based mitomycin chemoablation agent approved for low-grade UTUC. Zusduri: RTGel-based chemoablative therapy approved for recurrent low-grade intermediate risk NMIBC. RTGel: proprietary reverse-thermal hydrogel formulation platform used in both approved products and pipeline candidates. Pipeline includes UGN-201 (intravesical imiquimod) and UGN-301 (anti-CTLA-4 antibody) for high-grade NMIBC, both investigated in clinical-stage combination programs.
Revenue Model
Product sales of Jelmyto and Zusduri, both prescription chemoablative therapies reimbursed through Medicare and third-party commercial payors. Revenue is transactional, generated on a per-unit dispensing basis to healthcare providers treating uro-oncology patients.
Customers & Markets
Healthcare providers treating uro-oncology patients, including urologists at hospitals, surgery centers, and outpatient clinics in the United States. End markets are low-grade UTUC and recurrent low-grade intermediate risk NMIBC patient populations. Reimbursement depends on Medicare and third-party payor coverage decisions.
Geographic Exposure
United States commercial operations, as indicated by references to FDA-approved products, Medicare reimbursement, and U.S.-focused sales infrastructure. Subject to foreign regulations for any international clinical activity.
Financial Snapshot
Loading...
